Initiator Pharma
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.
INITIATOR PHARMA: Q1 2022 REPORT
MARKN.
Business highlights in Q1 2022
- On January 20th the initiation of dosing in the IPTN2021 program Phase 1 to assess pain reducing effects in healthy volunteers was announced.
- On March 22nd it was announced that the inclusion of test subjects in the IPTN2021 Phase 1 study had been completed.
Business highlights after this reporting period
- On April 5th the Company announced that it has signed an option agreement for a Phase 2/3 ready drug asset for an undisclosed pain indication.
- On April 13th the Board of Directors proposed a directed share issue and fully guaranteed rights issue of a total of approximately SEK 61 million to finance its clinical programs into the beginning of 2024.
Financial Highlights
| First Quarter (2022-01-01 – 2022-03-31) |
| Net revenues were TDKK 0 (0) |
| Operating loss, EBIT was TDKK -15 075 (-1 792) |
| Earnings per share was DKK –0.35 (-0.07) |
| Earnings per share, fully diluted, was DKK –0.31 (-0.06) |
| Cash: TDKK 26,352 (34,346) |
| Solidity: 65% (92%) |
Solidity: equity divided by assets.
The Board of Directors have decided that future interim reports will be published in English only.
Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/
| Datum | 2022-05-06, kl 08:30 |
| Källa | MFN |